KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accounts Payables (2018 - 2025)

Esperion Therapeutics' Accounts Payables history spans 8 years, with the latest figure at $65.1 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 25.98% year-over-year to $65.1 million; the TTM value through Dec 2025 reached $65.1 million, up 25.98%, while the annual FY2025 figure was $65.1 million, 25.98% up from the prior year.
  • Accounts Payables reached $65.1 million in Q4 2025 per ESPR's latest filing, down from $77.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $77.5 million in Q3 2025 to a low of $12.8 million in Q2 2022.
  • Average Accounts Payables over 5 years is $36.5 million, with a median of $28.9 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: plummeted 66.22% in 2021, then surged 153.21% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $17.6 million in 2021, then surged by 31.21% to $23.0 million in 2022, then surged by 37.66% to $31.7 million in 2023, then surged by 62.84% to $51.6 million in 2024, then increased by 25.98% to $65.1 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Accounts Payables are $65.1 million (Q4 2025), $77.5 million (Q3 2025), and $74.7 million (Q2 2025).